[A case of giant advanced breast cancer responding remarkably to chemo-endocrine therapy chiefly with doxifluridine].
A 68-year-old woman presented with advanced ulcerative breast cancer of the precordium; edema of the face, cervix and bilateral upper extremities; dyspnea from carcinomatous pleurisy; and multiple bone metastases, which suggested a terminal state. Her general condition improved with symptomatic therapies; thus, doxifluridine (5'-DFUR) and an endocrine therapeutic drug were given to reduce the primary focus, eliminate the edemas and decrease the plural effusion. When the tumor markers increased again, CEFT therapy [cyclophosphamide (CPA), epirubicin (epi-ADM), 5-fluorouracil (5-FU) and tamoxifen (TAM)] was conducted. This resulted in no adverse drug reaction, further reduction of the primary focus, and extremely improved Performance status (PS). The patient was discharged on 5'-DFUR and TAM therapy, which resulted in scarring of the ulcer, normalization of tumor marker levels, disappearance of the pleural effusion, and a reduction of metastatic bone foci. The findings suggest 5'-DFUR and endocrine therapeutic drugs can have a favorable clinical effect without impacting QOL and should be employed in patients with advanced cancer and poor general condition.